Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Top 6: What is EU HTA and why should statisticians care?

36:08
 
Share
 

Manage episode 503926849 series 2400265
Content provided by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Interview with Lara Wolfson and Anders Gorst-Rasmussen

Why You Should Listen:

EU HTA is becoming reality: Joint Clinical Assessments begin soon with oncology/ATMPs and will expand to all medicines over the next years.

Statisticians are central: Re-analyses, indirect comparisons, RWE, and quality-of-life analyses will be required—often beyond what regulatory trials were designed for.

Timelines are tight: From EMA Day 120 scoping to dossier deadlines and final JCAs just 30 days post-marketing authorization.

Transparency and resources matter: Joint assessments will be public, and both companies and agencies face capacity and clarity challenges.

You can prepare now: Incorporate HTA needs into trial design, analysis planning, and cross-functional collaborations.

Episode Highlights:

00:00 – 02:30 | I introduce the episode and explain why EU HTA is such a critical topic

02:30 – 05:30 | Lara and Anders introduce themselves and their HTA work at MSD and Novo Nordisk

05:30 – 10:45 | Regulatory vs. HTA: safe & effective vs. how good, for whom, and at what cost

10:45 – 18:30 | Europe’s patchwork: national differences in comparators, standards of care, and access

18:30 – 23:45 | The EU regulation: joint clinical assessments, economic modeling, and what’s changing

23:45 – 32:30 | What it means for us as statisticians: re-analyses, ITCs/NMAs, RWE, QoL, and capacity issues

32:30 – 36:00 | Why “transparency” can’t just be 50,000-page PDFs—clear, reproducible evidence matters

36:00 – 45:00 | The PSI HTA SIG’s role, current activities, and how you can get involved

45:00 – end | Our final takeaways and a call for statisticians to engage now

Links:

🔗 Join the PSI HTA Special Interest Group and watch for their newsletter and training.

🔗 Review EUnetHTA 21 methodological drafts—they are shaping the future of JCAs.

🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.

🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.

🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.

🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.

Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.

Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.

Glossary:

HTA – Health Technology Assessment

EU HTA / JCA – Joint Clinical Assessment forming the evidence base for national HTA decisions

EMA / CHMP – European Medicines Agency / Committee for Medicinal Products for Human Use

RWE – Real-World Evidence; NMA/ITC – Network/Indirect Treatment Comparison

QoL/HRQoL – (Health-Related) Quality of Life measures

PSI HTA SIG – PSI Special Interest Group on HTA

EFPIA – European Federation of Pharmaceutical Industries and Associations

  continue reading

462 episodes

Artwork
iconShare
 
Manage episode 503926849 series 2400265
Content provided by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Interview with Lara Wolfson and Anders Gorst-Rasmussen

Why You Should Listen:

EU HTA is becoming reality: Joint Clinical Assessments begin soon with oncology/ATMPs and will expand to all medicines over the next years.

Statisticians are central: Re-analyses, indirect comparisons, RWE, and quality-of-life analyses will be required—often beyond what regulatory trials were designed for.

Timelines are tight: From EMA Day 120 scoping to dossier deadlines and final JCAs just 30 days post-marketing authorization.

Transparency and resources matter: Joint assessments will be public, and both companies and agencies face capacity and clarity challenges.

You can prepare now: Incorporate HTA needs into trial design, analysis planning, and cross-functional collaborations.

Episode Highlights:

00:00 – 02:30 | I introduce the episode and explain why EU HTA is such a critical topic

02:30 – 05:30 | Lara and Anders introduce themselves and their HTA work at MSD and Novo Nordisk

05:30 – 10:45 | Regulatory vs. HTA: safe & effective vs. how good, for whom, and at what cost

10:45 – 18:30 | Europe’s patchwork: national differences in comparators, standards of care, and access

18:30 – 23:45 | The EU regulation: joint clinical assessments, economic modeling, and what’s changing

23:45 – 32:30 | What it means for us as statisticians: re-analyses, ITCs/NMAs, RWE, QoL, and capacity issues

32:30 – 36:00 | Why “transparency” can’t just be 50,000-page PDFs—clear, reproducible evidence matters

36:00 – 45:00 | The PSI HTA SIG’s role, current activities, and how you can get involved

45:00 – end | Our final takeaways and a call for statisticians to engage now

Links:

🔗 Join the PSI HTA Special Interest Group and watch for their newsletter and training.

🔗 Review EUnetHTA 21 methodological drafts—they are shaping the future of JCAs.

🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.

🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.

🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.

🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.

Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.

Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.

Glossary:

HTA – Health Technology Assessment

EU HTA / JCA – Joint Clinical Assessment forming the evidence base for national HTA decisions

EMA / CHMP – European Medicines Agency / Committee for Medicinal Products for Human Use

RWE – Real-World Evidence; NMA/ITC – Network/Indirect Treatment Comparison

QoL/HRQoL – (Health-Related) Quality of Life measures

PSI HTA SIG – PSI Special Interest Group on HTA

EFPIA – European Federation of Pharmaceutical Industries and Associations

  continue reading

462 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play